

(51) International Patent Classification 4 : C12P 21/02, G01N 33/53 // C07K 15/18, C07H 21/04 C12N 15/00 (C12N 5:00 C12R 1:91)		A1	(11) International Publication Number: WO 89/ 02472  (43) International Publication Date: 23 March 1989 (23.03.89)
(21) International Application Number: PCT/AU88/00370 (22) International Filing Date: 21 September 1988 (21.09.88)  (31) Priority Application Numbers: PI 4493 PI 6787 (32) Priority Dates: 21 September 1987 (21.09.87) 16 February 1988 (16.02.88) (33) Priority Country: AU  (71) Applicant (for all designated States except US): AM- RAD CORPORATION LIMITED [AU/AU]; 663 Victoria Street, Abbotsford, VIC 3067 (AU).  (72) Inventors; and (75) Inventors/Applicants (for US only): SHANNON, Mary, Frances [IE/AU]; 8 the Crescent, Crafers, S.A. 5152 (AU). VADAS, Mathew, Alexander [AU/AU]; 8 Branch Road, Stirling, S.A. 5152 (AU).		(74) Agents: SLATTERY, John, Michael et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).  (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report</i> <i>With amended claims.</i>  Date of publication of the amended claims: 20 April 1989 (20.04.89)	
(54) Title: REGULATION OF EXPRESSION OF GM-CSF GENE			
	<u>GENE</u>	<u>SEQUENCE</u>	
	hGM-CSF (5)	-96 GGAGATTCCACAGTTCAGGTA -75	
	mGM-CSF (15)	-108 GGAGATTCCACAacTCAGGTA -88	
	hIL-3 (Yang et al, in press)	GGAGgTTCCA†-G-TCAGaTA	
	hIL-3 (31)	-115 GGAGgTTCCA†-G-TCAGaTA -97	
	hIL-2 (32)	-198 aGgGATT†CACctaca†ccat -178	
	mIL-2 (33)	-208 aGgGATT†CACc‡aaatccat -188	
	hG-CSF (34)	-188 aGAGATTCCACAaTT†cacaa -168	
(57) Abstract	mG-CSF (16)	-172 aGAGATTCCcCgaTT†cacaa -172	
<p>A method for controlling the expression of granulocyte/macrophage colony stimulating factor (GM-CSF) in cells which express GM-CSF, or for controlling the expression of other haemopoietic cytokines which contain the Ck-1 or Ck-2 DNA sequences in cells where they are expressed, which comprises the step of regulation of the binding of nuclear protein(s) in said cells with Ck-1 and Ck-2 in the promoter region of the GM-CSF gene or the said haemopoietic cytokine genes. The step of regulation of the binding of the nuclear protein(s) with Ck-1 and Ck-2 sequences may consist of the induction or promotion of binding, or alternatively, it may consist of the prevention or inhibition of binding. By way of example, regulation of the binding of the nuclear protein(s) may be effected by the use of DNA of a sequence which will act as a competitive inhibitor in the binding of protein(s).</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

## AMENDED CLAIMS

[received by the International Bureau on 13 March 1989 (13.03.89),  
original claim 1 amended; remaining claims unchanged (2 pages)]

- 1.(Amended) A method for controlling the expression of granulocyte/macrophage colony stimulating factor (GM-CSF) in cells which express GM-CSF, or for controlling the expression of other haemopoietic cytokines containing CK-1 or CK-2 in cells where they are expressed, which comprises the step of regulation of the binding of nuclear protein(s) in said cells with the promoter region of the GM-CSF gene or said haemopoietic cytokine genes.
2. A method according to claim 1, wherein said regulation step comprises induction or promotion of said binding of nuclear protein(s) with said promoter region.
3. A method according to claim 1, wherein said regulation step comprises prevention or inhibition of said binding of nuclear protein(s) with said promoter region.
4. A method according to claim 1, wherein said regulation step comprises regulation of binding of said nuclear protein(s) to the region spanning the cytokine-1 (CK-1) and/or cytokine-2 (CK-2) specific sequences of the promoter region of the GM-CSF gene.
5. A method according to claim 4, wherein said regulation step comprises induction of the formulation of the NF-GMa and/or NF-GMb complexes by interaction of nuclear protein(s) with said region spanning the CK-1 and/or CK-2 specific sequences.
6. A method of diagnosis of diseases associated with abnormalities in the expression of GM-CSF, which comprises the step of detection of abberations or abnormalities in

the identities of nuclear protein(s) in GM-CSF expressing cells, in the promoter region of the GM-CSF gene in said cells, or in the nature of binding of said nuclear protein(s) with said promoter region.

7. A method of diagnosis of diseases associated with the expression of GM-CSF which comprises the step of detection of the NF-GMa and/or NF-GMb nuclear protein(s) in cell samples taken from a patient.

8. A method for the determination of an agent which is effective in controlling the binding of nuclear protein(s) with the promoter region of GM-CSF gene in cells which express GM-CSF, which comprises the step of screening the effect of a candidate agent on a nuclear extract in a gel retardation assay.